Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?

Sensus outlines shift to $250,000 average selling price as it targets a stronger second half

2026/08/14

Rekor targets adjusted EBITDA profitability in H2 2026 as GoSecure expands into audio

2026/08/14

Tenon outlines sacropelvic launches over next six to nine months following FDA 510(k) clearance

2026/08/14

Daré Bioscience targets Ovaprene top-line data in 2027 as it plans DARE to PLAY dispensing this quarter

2026/08/14